Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever

Rosemary Wyber, Ben Boyd, Samantha Colquhoun, Bart Currie, Mark Emmanuel Engel, Joseph Kado, Ganesan Karthikeyan, Mark Sullivan, Anita Saxena, Meru Sheel, Andrew Steer, Joseph Mucumbitsi, Liesl Zuhlke, Jonathan Carapetis

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
    Original languageEnglish
    Pages (from-to)572-578
    Number of pages7
    JournalDrug Delivery and Translational Research
    Volume6
    Issue number5
    DOIs
    Publication statusPublished - Oct 2016

    Fingerprint

    Penicillin G Benzathine
    Rheumatic Fever
    Referral and Consultation
    Rheumatic Heart Disease
    Streptococcal Infections
    Antibiotic Prophylaxis
    Refrigeration
    Costs and Cost Analysis
    Recurrence
    Pain

    Cite this

    Wyber, Rosemary ; Boyd, Ben ; Colquhoun, Samantha ; Currie, Bart ; Engel, Mark Emmanuel ; Kado, Joseph ; Karthikeyan, Ganesan ; Sullivan, Mark ; Saxena, Anita ; Sheel, Meru ; Steer, Andrew ; Mucumbitsi, Joseph ; Zuhlke, Liesl ; Carapetis, Jonathan. / Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. In: Drug Delivery and Translational Research. 2016 ; Vol. 6, No. 5. pp. 572-578.
    @article{13a836f6aac34adbb8e605e6b4606572,
    title = "Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever",
    abstract = "Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.",
    author = "Rosemary Wyber and Ben Boyd and Samantha Colquhoun and Bart Currie and Engel, {Mark Emmanuel} and Joseph Kado and Ganesan Karthikeyan and Mark Sullivan and Anita Saxena and Meru Sheel and Andrew Steer and Joseph Mucumbitsi and Liesl Zuhlke and Jonathan Carapetis",
    year = "2016",
    month = "10",
    doi = "10.1007/s13346-016-0313-z",
    language = "English",
    volume = "6",
    pages = "572--578",
    journal = "Drug Delivery and Translational Research",
    issn = "2190-393X",
    publisher = "Springer",
    number = "5",

    }

    Wyber, R, Boyd, B, Colquhoun, S, Currie, B, Engel, ME, Kado, J, Karthikeyan, G, Sullivan, M, Saxena, A, Sheel, M, Steer, A, Mucumbitsi, J, Zuhlke, L & Carapetis, J 2016, 'Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever', Drug Delivery and Translational Research, vol. 6, no. 5, pp. 572-578. https://doi.org/10.1007/s13346-016-0313-z

    Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. / Wyber, Rosemary; Boyd, Ben; Colquhoun, Samantha; Currie, Bart; Engel, Mark Emmanuel; Kado, Joseph; Karthikeyan, Ganesan; Sullivan, Mark; Saxena, Anita; Sheel, Meru; Steer, Andrew; Mucumbitsi, Joseph; Zuhlke, Liesl; Carapetis, Jonathan.

    In: Drug Delivery and Translational Research, Vol. 6, No. 5, 10.2016, p. 572-578.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever

    AU - Wyber, Rosemary

    AU - Boyd, Ben

    AU - Colquhoun, Samantha

    AU - Currie, Bart

    AU - Engel, Mark Emmanuel

    AU - Kado, Joseph

    AU - Karthikeyan, Ganesan

    AU - Sullivan, Mark

    AU - Saxena, Anita

    AU - Sheel, Meru

    AU - Steer, Andrew

    AU - Mucumbitsi, Joseph

    AU - Zuhlke, Liesl

    AU - Carapetis, Jonathan

    PY - 2016/10

    Y1 - 2016/10

    N2 - Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.

    AB - Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.

    UR - http://www.scopus.com/inward/record.url?scp=84983604692&partnerID=8YFLogxK

    U2 - 10.1007/s13346-016-0313-z

    DO - 10.1007/s13346-016-0313-z

    M3 - Article

    VL - 6

    SP - 572

    EP - 578

    JO - Drug Delivery and Translational Research

    JF - Drug Delivery and Translational Research

    SN - 2190-393X

    IS - 5

    ER -